CN114235906B - Method for detecting blood glucose concentration in real time in-vitro blood glucose degradation process - Google Patents
Method for detecting blood glucose concentration in real time in-vitro blood glucose degradation process Download PDFInfo
- Publication number
- CN114235906B CN114235906B CN202111317693.3A CN202111317693A CN114235906B CN 114235906 B CN114235906 B CN 114235906B CN 202111317693 A CN202111317693 A CN 202111317693A CN 114235906 B CN114235906 B CN 114235906B
- Authority
- CN
- China
- Prior art keywords
- blood
- blood glucose
- parameter
- hct
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000004369 blood Anatomy 0.000 title claims abstract description 203
- 239000008280 blood Substances 0.000 title claims abstract description 203
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title claims abstract description 115
- 239000008103 glucose Substances 0.000 title claims abstract description 115
- 238000000034 method Methods 0.000 title claims abstract description 70
- 238000006731 degradation reaction Methods 0.000 title claims abstract description 59
- 238000000338 in vitro Methods 0.000 title claims abstract description 24
- 230000015556 catabolic process Effects 0.000 claims abstract description 43
- 238000005534 hematocrit Methods 0.000 claims abstract description 29
- 230000000593 degrading effect Effects 0.000 claims abstract description 5
- 238000004364 calculation method Methods 0.000 claims description 29
- 210000003743 erythrocyte Anatomy 0.000 claims description 23
- 238000012360 testing method Methods 0.000 claims description 11
- 238000005119 centrifugation Methods 0.000 claims description 6
- 239000011521 glass Substances 0.000 claims description 6
- 238000004820 blood count Methods 0.000 claims description 2
- 238000001514 detection method Methods 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000012544 monitoring process Methods 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 3
- 238000012795 verification Methods 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000000835 electrochemical detection Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003924 normoblast Anatomy 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
Abstract
A method for detecting blood glucose concentration in real time in an in-vitro blood glucose degradation process, comprising the following steps: step one, obtaining a hematocrit HCT parameter in an isolated blood sample, and then adjusting the hematocrit HCT parameter to be within a preset range; step two, obtaining the initial blood glucose concentration C of the isolated blood sample treated in the step one Initially, the method comprises The method comprises the steps of carrying out a first treatment on the surface of the Setting the temperature T of the sample chamber in degrees centigrade, and according to the adjusted HCT parameter and the initial blood sugar concentration C Initially, the method comprises And the temperature T, and calculating the blood glucose degradation rate K through an empirical formula. Step four, degrading the isolated blood sample for a period of time t; the method is divided into: t is not less than 4<17, and 0.ltoreq.t<1, the time is 1; t is not less than 4<17, and t is more than or equal to 1; when T is more than or equal to 17 and less than or equal to 37; t and T are in different ranges, and a corresponding formula is selected to calculate the blood glucose concentration C of the real-time in-vitro blood sample Real world 。
Description
Technical Field
The invention relates to the technical field of electrochemical detection, in particular to a method for detecting blood glucose concentration in real time in an in-vitro blood glucose degradation process.
Background
Along with technological progress and changes of human living habits, the field of home care is getting more and more important, and besides the real-time condition of patients can be mastered at any time, a plurality of inspection projects which originally need to be carried out in hospitals are developed to home autonomous measurement.
Diabetes is a common household care disease, and monitoring of blood glucose level is one of important care projects for diabetics. Blood glucose meters on the market at present can be used for testing blood glucose by venous blood and capillary blood, wherein the blood glucose meter and test paper performance are most conveniently tested by capillary blood samples, but a large amount of isolated blood is required for testing in clinic or laboratory, and the capillary blood is small in quantity and difficult to collect, so that the blood glucose meter and test paper performance are usually analyzed by adopting venous blood to replace capillary blood, and in order to ensure the accuracy of analysis, isolated blood samples with different blood glucose concentrations are usually required to be configured. In addition, when developing new blood glucose test strips and instruments, the calibrated parameters are tested by in vitro blood samples with different blood glucose concentrations.
When the blood glucose concentration is lower than the target range, the blood glucose concentration is increased by adding glucose solution into the blood sample; however, when the blood glucose concentration is higher than the target range, only a room temperature standing method can be adopted to degrade the glucose in the blood sample when the blood glucose concentration is to be reduced, the blood glucose concentration is automatically reduced, and the blood glucose concentration of the blood sample is detected at intervals. The method for detecting the blood sugar concentration at intervals for many times in the glucose degradation process is complex in operation, time-consuming and labor-consuming, and can often cause the blood sugar concentration to be lower than a target range, and glucose solution is needed to be added to improve the blood sugar concentration, so that repeated adjustment is possible to reach the target range.
In view of this, it is the subject of the present invention to design a method for detecting the blood glucose concentration in real time during the glucose degradation process and improving the efficiency of preparing the blood sample for the isolated blood sample having the blood glucose concentration higher than the target range.
Disclosure of Invention
The invention aims to provide a method for detecting blood glucose concentration in real time in an in-vitro blood glucose degradation process.
In order to achieve the above purpose, the invention adopts the following technical scheme:
a method for detecting blood glucose concentration in real time in an in vitro blood glucose degradation process, the detection method comprising the following steps:
step one, obtaining a hematocrit HCT parameter in an isolated blood sample, wherein the unit is percentage, and then adjusting the hematocrit HCT parameter to be within a preset range;
step two, obtaining the initial blood glucose concentration C of the isolated blood sample treated in the step one Initially, the method comprises The unit is mg/dL;
setting the temperature T of the sample chamber in degrees centigrade, and according to the adjusted HCT parameter and the initial blood sugar concentration C Initially, the method comprises And the temperature T, the blood sugar degradation rate K is calculated, and the calculation formula is as follows:
；
wherein: a is a constant coefficient, and the value range of the constant coefficient is-2 and less than 0;
b is a constant coefficient, and the value range of B is-25 to less than 0;
c is a constant coefficient, and the value range of C is more than 0 and less than or equal to 0.5;
d is a constant coefficient, and the value range of D is more than 0 and less than or equal to 1;
e is a constant coefficient, and the value range of E is more than 0 and less than or equal to 40;
f is a constant coefficient, and the value range of F is more than 0 and less than or equal to 10;
eis a natural constant;
step four, degrading the in-vitro blood sample for a period of time t, wherein the unit is hour;
when 4 is less than or equal to T<17, and 0.ltoreq.t<1, according to the blood glucose degradation rate K and the initial blood glucose concentration C Initially, the method comprises And degradation time t, and a calculation formula:
C real world =C Initially, the method comprises +K*t （2）
Calculation ofObtaining the blood sugar concentration C of the real-time in-vitro blood sample Real world The unit is mg/dL;
when 4 is less than or equal to T<17, and when t is more than or equal to 1, calculating the blood glucose concentration C at the time t-1 t-1 And then according to the degradation rate K and degradation time t of blood sugar and a calculation formula:
C real world = C t-1 +K*t （3）
When T is more than or equal to 17 and less than or equal to 37, according to the degradation rate K of blood sugar and the initial blood sugar concentration C Initially, the method comprises And degradation time t, and a calculation formula:
C real world =C Initially, the method comprises +K*t （4）
Calculating to obtain the blood glucose concentration C of the real-time in-vitro blood sample Real world The unit is mg/dL.
The relevant content explanation in the technical scheme is as follows:
1. in the scheme, the hematocrit HCT parameter is also called hematocrit, and is the relative proportion of the volume occupied by the erythrocytes in a certain volume, generally, the hematocrit HCT parameter is basically 40% -50% of normal men; the HCT of normal women is basically 37% -48%. However, HCT may be less than 35% or greater than 50% for a patient or particular population.
2. In the scheme, the calculation formulas of the third step and the fourth step are that the inventor measures a plurality of groups of packed red blood cell HCT parameters and initial blood sugar concentration C of people with different sexes and ages through a great amount of experimental study and verification Initially, the method comprises And temperature T, and measuring the real-time blood glucose concentration C during glucose degradation at a plurality of sets of degradation times T Real world And then carrying out formula fitting according to the obtained database, and optimizing the obtained formula, wherein the value range of ABCDEF in the step three is the value range of overlapping of a plurality of blood samples, so that the calculation formula in the step three can be suitable for different types of people. And according to the temperature and degradation time, different calculation formulas are correspondingly selected, so as to improve the accuracy of calculation. According to the calculation formulas, the blood glucose concentration C of the isolated blood sample can be detected in real time Real world The blood sample in the required blood glucose concentration range is selected in a targeted way, so that the monitoring efficiency of the blood glucose monitoring system for self-test is improved. And can be seen by equation 1The blood sugar degradation rate K is related to the hematocrit HCT parameter and the temperature T, and the blood sugar degradation rate K can be improved by improving the hematocrit HCT parameter and/or the temperature T, so that the blood sugar degradation is accelerated, the operation is simple, the interference factors are few, the detection time of a blood sugar monitoring system for self-test is saved, and the detection efficiency is improved.
3. In the above scheme, the method for obtaining the hematocrit HCT parameter in the isolated blood sample by adopting the centrifugation method comprises the specific steps of placing the isolated blood sample in a Wittig tube or a capillary glass tube with uniform aperture, layering the isolated blood sample after centrifugation, and calculating the volume ratio of the reduced erythrocyte layer to the whole blood to obtain the hematocrit HCT parameter.
Centrifugation is a routine procedure for the WHO recommended HCT determination and can be accomplished by those skilled in the art, including the wen's method, the micro-method. The specific embodiments and parameter requirements of the centrifugation method are all the prior art.
The procedure of the Winchi method can be that 2ml of the isolated blood sample is taken and added into a Winchi tube, the blood is centrifuged for 30 minutes with a horizontal centrifuge at the rotation speed of 22.5cm with the effective radius of 3000r/min, and the blood is divided into 5 layers from top to bottom, namely a plasma layer, a platelet layer, a leucocyte layer, a nucleated erythrocyte layer, a reduced erythrocyte layer (purple black) and an oxygenated erythrocyte layer (bright red). The number of millimeters of the column height of the reduced erythrocyte layer is read and multiplied by 0.01, namely the number of liters of the volume of the erythrocyte in each liter of blood.
The operation steps of the micro method can be that the isolated blood sample is taken and filled into 2/3 parts of the disposable capillary glass tube, the length of the disposable capillary glass tube is 75mm, the inner diameter is about 0.8-1.0 mm, the wall thickness is 0.20-0.25 mm, and the 2/3 parts of the disposable capillary glass tube are 50 mm. Sealing again, centrifuging at 12000r/min with a horizontal capillary Hct centrifuge for 5min, reading the reduced erythrocyte layer and full layer length with a special reading plate or scale, and calculating the packed volume HCT parameter of the erythrocyte.
4. In the scheme, a blood analyzer is adopted to obtain the average volume MCV parameter and the RBC parameter of the red blood cell count, and then the formula is adopted:
HCT=MCV×RBC （3）
and calculating and obtaining the HCT parameter of the hematocrit.
Hematology analyzers are also conventional methods in the art for obtaining packed red blood cell HCT parameters, and the specific embodiments and parameters are well within the skill of the art. The principle is that when the cells pass through the counting small holes, pulses with corresponding sizes are formed, the number of the pulses is the number of the cells, the pulse height is the cell volume, and the hematocrit is obtained through the average volume of red blood cells (MCV) and the count of Red Blood Cells (RBC).
5. In the above scheme, the specific step of adjusting the HCT parameter of the hematocrit to be within the preset range is to add plasma to the isolated blood sample if the HCT parameter is higher than the preset range; if the HCT parameter is lower than the preset range, removing part of plasma in the isolated blood sample.
The preset range is set manually by a person skilled in the art and can be flexibly adjusted according to specific requirements.
6. In the scheme, the initial blood glucose concentration C is obtained by testing by using a YSI2300 glucose analyzer Initially, the method comprises . The YSI2300 glucose analyzer is a prior art, and therefore, the disclosure is not repeated.
7. In the scheme, the value of A is-1.2, the value of B is-21.45, the value of C is 0.42, the value of D is 0.15, the value of E is 22.4, and the value of F is 4.23. By adopting the value taking condition, the accuracy of the calculation formula is higher.
8. In the scheme, the value of A is-0.8, the value of B is-24.2, the value of C is 0.43, the value of D is 0.2, the value of E is 14.8 and the value of F is 3.4.
9. In the above scheme, in the first step, the preset range of the packed red blood cell HCT parameter is 30% -60%.
The working principle of the invention is as follows: the invention firstly acquires the HCT parameter of the hematocrit in the isolated blood sample, then adjusts the HCT parameter to be within a preset range, and then measures the initial blood glucose concentration C of the isolated blood sample Initially, the method comprises Setting the temperature T of a sample chamber, calculating the degradation rate K of blood sugar according to a formula 1, degrading for a period of time T, and calculating the real-time blood sugar concentration C according to a formula 2 Real world 。
Due to the application of the technical scheme, compared with the prior art, the invention has the following advantages and effects:
1. the invention has simple operation method, and in the degradation process of the in-vitro blood glucose, the initial blood glucose concentration C is calculated according to the formula of the degradation rate of the blood glucose Initially, the method comprises And the degradation time t can calculate the real-time blood sugar concentration C Real world Through verification of multiple groups of experimental data, the calculation method is accurate and reliable, and the problem that the blood glucose concentration cannot be detected in real time in the prior art is solved.
The detection method does not need to detect the blood glucose concentration for multiple times at intervals in the glucose degradation process, can detect the blood glucose concentration in real time, controls the glucose degradation termination time according to the target range, prepares the blood sample, avoids repeatedly adjusting the blood glucose concentration, saves time and labor, and improves the efficiency of preparing the blood sample.
2. In the detection process, the blood glucose degradation rate K can be improved by improving the HCT parameter and/or the temperature T, so that the glucose degradation is accelerated, the time for manufacturing the blood sample is shortened, the operation is simple, the interference factors are few, and the efficiency for manufacturing the blood sample is improved.
In a word, the method for detecting the blood glucose concentration in real time in the in-vitro blood glucose degradation process is simple to operate, not only can the blood glucose concentration be detected in real time in the degradation process by a calculation formula, but also the blood glucose degradation rate K can be improved by improving the HCT parameter and/or the temperature T of the hematocrit, the glucose degradation is accelerated, the time for manufacturing the blood sample is shortened, and the efficiency for manufacturing the blood sample is improved.
In the past, the mode of detecting the blood sugar concentration at intervals for many times in the natural degradation process of the in-vitro blood glucose has the defects of complex operation, time and labor waste, repeated adjustment of the blood sugar concentration possibly required, and low efficiency in manufacturing the blood sample.
Drawings
FIG. 1 is a graph showing the degradation rate of blood glucose at different HCT parameters and temperatures T in accordance with an embodiment of the present invention.
Description of the embodiments
The invention is further described below with reference to the accompanying drawings and examples:
example 1:
a method for detecting blood glucose concentration in real time in an in vitro blood glucose degradation process, the detection method comprising the following steps:
step one, obtaining a hematocrit HCT parameter in an isolated blood sample, wherein the unit is percentage, and then adjusting the hematocrit HCT parameter to be within a preset range; the preset range of the hematocrit HCT parameter of this embodiment is 30% -60%. The embodiment adopts a centrifugal method to obtain the hematocrit HCT parameter in an isolated blood sample, and the specific steps include placing the isolated blood sample in a Wildet tube or a capillary glass tube with uniform aperture, layering the isolated blood sample after centrifugation, calculating the volume ratio of a reduced erythrocyte layer to whole blood, and obtaining the hematocrit HCT parameter. The specific step of adjusting the hematocrit HCT parameter to within a predetermined range is to add plasma to an ex-vivo blood sample if the HCT parameter is above the predetermined range; if the HCT parameter is lower than the preset range, removing part of plasma in the isolated blood sample.
In the practice of this example, the HCT parameters were selected from 30%, 42%, 50% and 60%.
Step two, obtaining the initial blood glucose concentration C of the isolated blood sample treated in the step one Initially, the method comprises The unit is mg/dL; obtaining the initial blood glucose concentration C by testing with YSI2300 glucose analyzer Initially, the method comprises 。
Setting the temperature T of the sample chamber in degrees centigrade, and according to the adjusted HCT parameter and the initial blood sugar concentration C Initially, the method comprises And the temperature T, the blood sugar degradation rate K is calculated, and the calculation formula is as follows:
；
wherein: a is a constant coefficient, and the value range of the constant coefficient is-2 and less than 0;
b is a constant coefficient, and the value range of B is-25 to less than 0;
c is a constant coefficient, and the value range of C is more than 0 and less than or equal to 0.5;
d is a constant coefficient, and the value range of D is more than 0 and less than or equal to 1;
e is a constant coefficient, and the value range of E is more than 0 and less than or equal to 40;
f is a constant coefficient, and the value range of F is more than 0 and less than or equal to 10;
eis a natural constant;
in this example, the A value is-1.2, the B value is-21.45, the C value is 0.42, the D value is 0.15, the E value is 22.4, and the F value is 4.23.
Step four, degrading the in-vitro blood sample for a period of time t, wherein the unit is hour;
when 4 is less than or equal to T<17, and 0.ltoreq.t<1, according to the blood glucose degradation rate K and the initial blood glucose concentration C Initially, the method comprises And degradation time t, and a calculation formula:
C real world =C Initially, the method comprises +K*t （2）
Calculating to obtain the blood glucose concentration C of the real-time in-vitro blood sample Real world The unit is mg/dL;
when 4 is less than or equal to T<17, and when t is more than or equal to 1, calculating the blood glucose concentration C at the time t-1 t-1 And then according to the degradation rate K and degradation time t of blood sugar and a calculation formula:
C real world = C t-1 +K*t （3）
When T is more than or equal to 17 and less than or equal to 37, according to the degradation rate K of blood sugar and the initial blood sugar concentration C Initially, the method comprises And degradation time t, and a calculation formula:
C real world =C Initially, the method comprises +K*t （4）
Calculating to obtain the blood glucose concentration C of the real-time in-vitro blood sample Real world The unit is mg/dL.
According to the method for detecting blood glucose concentration, when the HCT parameter is selected to be 30%, C Initially, the method comprises Set to 120mg/dL; c when the HCT parameter is 42 percent Initially, the method comprises Set to 112mg/dL; when the HCT parameter is selected to be 50%, C Initially, the method comprises Set to 111mg/dL; when the HCT parameter is 60%, C Initially, the method comprises Set to 108mg/dL; and when t is 1h, 2h, 3h, 4h, 5h, 6h and 7h respectively, testing the blood glucose concentration by using a YSI2300 glucose analyzer to obtain a real-time measured value, and then calculating the blood glucose concentration according to a calculation formula in the detection method to obtain a real-time calculated value. And calculating a deviation value by the measured value and the calculated value, wherein the deviation=the calculated value/the measured value-1, and obtaining the data tables from table 1 to table 4.
TABLE 1 comparison of measured and calculated values for blood glucose concentration at a temperature of 4℃ for example 1
Connect the watch
Connect the watch
TABLE 2 example 1 comparison of measured and calculated values for blood glucose concentration at 17℃
Connect the watch
Connect the watch
TABLE 3 comparison of measured and calculated values for blood glucose concentration at a temperature of 23℃for example 1
Connect the watch
Connect the watch
TABLE 4 comparison of measured and calculated values for blood glucose concentration at 37℃for example 1
Connect the watch
Connect the watch
As can be seen from the comparison of the calculated values and measured values in tables 1 to 4, the deviation of the calculated values and the measured values is small, which indicates that the calculation method is accurate and has good correlation with the actual measured values, and the blood glucose concentration of the isolated blood sample can be detected in real time in a calculation mode, so that the detection efficiency is improved.
Referring to fig. 1, the data of tables 1 to 4 were statistically analyzed to obtain graphs of blood glucose degradation rates under different HCT parameters and temperature T conditions.
To further verify the accuracy of the calculation method of the invention, 10 in vitro blood samples with different HCT parameters are randomly selected, and different initial blood glucose concentrations C are set Initially, the method comprises And a sample chamber temperature T. And (5) measuring and calculating the real-time blood glucose concentration at random intervals for verification. See table 5 for specific data.
TABLE 5 different C Initially, the method comprises Comparison of measured and calculated values under T and HCT conditions
As can be seen from Table 5, the calculation method of the present invention is accurate at different initial blood glucose concentrations C Initially, the method comprises The method is applicable to the temperature T and HCT parameters of the sample chamber and different degradation times.
Example 2:
a method for detecting blood glucose concentration in real time in an in-vitro blood glucose degradation process, and the difference between the embodiment 2 and the embodiment 1 is that: in example 2, the A value was-0.8, the B value was-24.2, the C value was 0.43, the D value was 0.2, the E value was 14.8, and the F value was 3.4. When the HCT parameter is selected to be 30%, C Initially, the method comprises Set to 140mg/dL; c when the HCT parameter is 42 percent Initially, the method comprises Set to 132mg/dL; when the HCT parameter is selected to be 50%, C Initially, the method comprises Set to 122mg/dL; when the HCT parameter is 60%, C Initially, the method comprises Set to 116mg/dL.
The measurement method and calculation method are the same as in example 1, and the data table of tables 6 to 9 are obtained.
TABLE 6 comparison of measured and calculated values for blood glucose concentration at a temperature of 4℃for example 2
Connect the watch
Connect the watch
TABLE 7 comparison of measured and calculated values for blood glucose concentration at 17℃for example 2
Connect the watch
Connect the watch
TABLE 8 comparison of measured and calculated values for blood glucose concentration at a temperature of 23℃for example 2
Connect the watch
Connect the watch
TABLE 9 comparison of measured and calculated values for blood glucose concentration at 37℃for example 2
Connect the watch
Connect the watch
As can be seen from the comparison of the calculated values and measured values in tables 6 to 9, the deviation of the calculated values and the measured values is small, which indicates that the calculation method is accurate and has good correlation with the actual measured values, and the blood glucose concentration of the isolated blood sample can be detected in real time in a calculation mode, so that the detection efficiency is improved.
The above embodiments are provided to illustrate the technical concept and features of the present invention and are intended to enable those skilled in the art to understand the content of the present invention and implement the same, and are not intended to limit the scope of the present invention. All equivalent changes or modifications made in accordance with the spirit of the present invention should be construed to be included in the scope of the present invention.
Claims (5)
1. A method for detecting the concentration of blood sugar in real time in the degradation process of in-vitro blood glucose is characterized by comprising the following steps: the method comprises the following steps:
step one, obtaining a hematocrit HCT parameter in percentage in an isolated blood sample, and then adjusting the hematocrit HCT parameter to a preset range, wherein the preset range of the hematocrit HCT parameter is 30% -60%;
step two, obtaining the initial blood glucose concentration C of the isolated blood sample treated in the step one Initially, the method comprises The unit is mg/dL;
setting the temperature T of the sample chamber in degrees centigrade, calculating the blood sugar degradation rate K according to the adjusted HCT parameter and the temperature T, and the calculation formula is as follows:
；
wherein: a is a constant coefficient, and the value range of the constant coefficient is-2 and less than 0;
b is a constant coefficient, and the value range of B is-25 to less than 0;
c is a constant coefficient, and the value range of C is more than 0 and less than or equal to 0.5;
d is a constant coefficient, and the value range of D is more than 0 and less than or equal to 1;
e is a constant coefficient, and the value range of E is more than 0 and less than or equal to 40;
f is a constant coefficient, and the value range of F is more than 0 and less than or equal to 10;
eis a natural constant;
step four, degrading the in-vitro blood sample for a period of time t, wherein the unit is hour;
when 4 is less than or equal to T<17, and 0.ltoreq.t<1, according to the blood glucose degradation rate K and the initial blood glucose concentration C Initially, the method comprises And degradation time t, and a calculation formula:
C real world =C Initially, the method comprises +K*t （2）
Calculating to obtain the blood glucose concentration C of the real-time in-vitro blood sample Real world The unit is mg/dL;
when 4 is less than or equal to T<17, and when t is more than or equal to 1, calculating the blood glucose concentration C at the time t-1 t-1 And then according to the degradation rate K and degradation time t of blood sugar and a calculation formula:
C real world = C t-1 +K*t （3）
When T is more than or equal to 17 and less than or equal to 37, according to the degradation rate K of blood sugar and the initial blood sugar concentration C Initially, the method comprises And degradation time t, and a calculation formula:
C real world =C Initially, the method comprises +K*t （4）
Calculating to obtain the blood glucose concentration C of the real-time in-vitro blood sample Real world The unit is mg/dL;
in the first step, a blood analyzer is adopted to obtain an average volume MCV parameter of red blood cells and an RBC parameter of red blood cell count, and then the method is based on the formula:
HCT=MCV×RBC （5）
calculating and obtaining HCT parameters of the hematocrit;
or in the first step, obtaining the hematocrit HCT parameter in the isolated blood sample by adopting a centrifugal method, specifically, placing the isolated blood sample in a Wildet tube or a capillary glass tube with uniform aperture, layering the isolated blood sample after centrifugation, and calculating the volume ratio of the reduced erythrocyte layer to the whole blood to obtain the hematocrit HCT parameter.
2. The method for detecting the concentration of blood glucose in real time during the degradation of glucose in blood ex vivo according to claim 1, wherein: in the first step, the specific step of adjusting the HCT parameter of the hematocrit to be within the preset range is to add plasma to the isolated blood sample if the HCT parameter is higher than the preset range; if the HCT parameter is lower than the preset range, removing part of plasma in the isolated blood sample.
3. The method for detecting the concentration of blood glucose in real time during the degradation of glucose in blood ex vivo according to claim 1, wherein: in step (2)In the second step, the initial blood glucose concentration C is obtained by testing by using a YSI2300 glucose analyzer Initially, the method comprises 。
4. The method for detecting the concentration of blood glucose in real time during the degradation of glucose in blood ex vivo according to claim 1, wherein: a is-1.2, B is-21.45, C is 0.42, D is 0.15, E is 22.4, and F is 4.23.
5. The method for detecting the concentration of blood glucose in real time during the degradation of glucose in blood ex vivo according to claim 1, wherein: a is-0.8, B is-24.2, C is 0.43, D is 0.2, E is 14.8, and F is 3.4.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111317693.3A CN114235906B (en) | 2021-11-09 | 2021-11-09 | Method for detecting blood glucose concentration in real time in-vitro blood glucose degradation process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111317693.3A CN114235906B (en) | 2021-11-09 | 2021-11-09 | Method for detecting blood glucose concentration in real time in-vitro blood glucose degradation process |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114235906A CN114235906A (en) | 2022-03-25 |
| CN114235906B true CN114235906B (en) | 2024-01-05 |
Family
ID=80748711
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111317693.3A Active CN114235906B (en) | 2021-11-09 | 2021-11-09 | Method for detecting blood glucose concentration in real time in-vitro blood glucose degradation process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114235906B (en) |
Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0407992A1 (en) * | 1989-07-13 | 1991-01-16 | Kyoto Daiichi Kagaku Co., Ltd. | Method for determination of glucose concentration |
| WO2013036836A2 (en) * | 2011-09-08 | 2013-03-14 | Fresenius Medical Care Holdings, Inc. | System and method of modeling erythropoiesis and its management |
| CA2891041A1 (en) * | 2012-12-04 | 2014-06-12 | F. Hoffmann-La Roche Ag | Method for hematocrit correction and glucose meter adapted therefor |
| CN108680622A (en) * | 2018-05-23 | 2018-10-19 | 北京乐普医疗科技有限责任公司 | Packed cell volume measures and the method for correction in a kind of electrochemica biological sensor |
| CN109884150A (en) * | 2019-03-08 | 2019-06-14 | 武汉璟泓万方堂医药科技股份有限公司 | A kind of red blood cell overstocks bearing calibration and storage medium |
| CN110346499A (en) * | 2018-04-04 | 2019-10-18 | 青岛大学附属医院 | Biomarker and application thereof in blood for detecting kidney |
| CN111239227A (en) * | 2020-02-24 | 2020-06-05 | 江苏鱼跃医疗设备股份有限公司 | Erythrocyte volume correction method and biosensor testing device |
| CN111982987A (en) * | 2020-08-27 | 2020-11-24 | 江苏鱼跃医疗设备股份有限公司 | Glucose sensor and measurement correction method |
| CN112305207A (en) * | 2020-10-20 | 2021-02-02 | 上海交通大学 | Based on HbA1cMethod for detecting average life of red blood cells by taking blood glucose concentration as sensing variable |
| KR20210027010A (en) * | 2019-08-30 | 2021-03-10 | 주식회사 비바이오 | Apparatus and method for measuring glucose |
| CN113558175A (en) * | 2021-08-10 | 2021-10-29 | 赞皇县光森中药材有限公司 | Method and device for degrading aflatoxin in spina date seeds |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0303249D0 (en) * | 2003-12-02 | 2003-12-02 | Inst Polymerutveckling Ab | Hematocrit and analyte concentration determination |
| US9289168B2 (en) * | 2008-12-29 | 2016-03-22 | Medtronic Minimed, Inc. | System and/or method for glucose sensor calibration |
| US11131645B2 (en) * | 2017-05-05 | 2021-09-28 | Trividia Health, Inc. | Methods and systems for hematocrit measurement |
-
2021
- 2021-11-09 CN CN202111317693.3A patent/CN114235906B/en active Active
Patent Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0407992A1 (en) * | 1989-07-13 | 1991-01-16 | Kyoto Daiichi Kagaku Co., Ltd. | Method for determination of glucose concentration |
| WO2013036836A2 (en) * | 2011-09-08 | 2013-03-14 | Fresenius Medical Care Holdings, Inc. | System and method of modeling erythropoiesis and its management |
| CA2891041A1 (en) * | 2012-12-04 | 2014-06-12 | F. Hoffmann-La Roche Ag | Method for hematocrit correction and glucose meter adapted therefor |
| CN110346499A (en) * | 2018-04-04 | 2019-10-18 | 青岛大学附属医院 | Biomarker and application thereof in blood for detecting kidney |
| CN108680622A (en) * | 2018-05-23 | 2018-10-19 | 北京乐普医疗科技有限责任公司 | Packed cell volume measures and the method for correction in a kind of electrochemica biological sensor |
| CN109884150A (en) * | 2019-03-08 | 2019-06-14 | 武汉璟泓万方堂医药科技股份有限公司 | A kind of red blood cell overstocks bearing calibration and storage medium |
| KR20210027010A (en) * | 2019-08-30 | 2021-03-10 | 주식회사 비바이오 | Apparatus and method for measuring glucose |
| CN111239227A (en) * | 2020-02-24 | 2020-06-05 | 江苏鱼跃医疗设备股份有限公司 | Erythrocyte volume correction method and biosensor testing device |
| CN111982987A (en) * | 2020-08-27 | 2020-11-24 | 江苏鱼跃医疗设备股份有限公司 | Glucose sensor and measurement correction method |
| CN112305207A (en) * | 2020-10-20 | 2021-02-02 | 上海交通大学 | Based on HbA1cMethod for detecting average life of red blood cells by taking blood glucose concentration as sensing variable |
| CN113558175A (en) * | 2021-08-10 | 2021-10-29 | 赞皇县光森中药材有限公司 | Method and device for degrading aflatoxin in spina date seeds |
Non-Patent Citations (2)
| Title |
|---|
| HbA1c体外代谢动力学研究;沈雄文等;临床检验研究论著;第33卷(第24期);第2988-2989页 * |
| 向根延等.临床检验手册.湖南科学技术出版社,2020,第166页. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114235906A (en) | 2022-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO1993012422A1 (en) | Method and apparatus for quantitation of relevant blood parameters | |
| CN108680622A (en) | Packed cell volume measures and the method for correction in a kind of electrochemica biological sensor | |
| Oral Anticoagulation Monitoring Study Group | Point-of-care prothrombin time measurement for professional and patient self-testing use: a multicenter clinical experience | |
| Prichard et al. | Clinical evaluation of the ABL-77 for point-of-care analysis in the cardiovascular operating room | |
| Cao et al. | Determination of clinically acceptable cut-offs for hemolysis index: An application of bootstrap method using real-world data | |
| Vanavanan et al. | Performance of a new interference-resistant glucose meter | |
| CN114235906B (en) | Method for detecting blood glucose concentration in real time in-vitro blood glucose degradation process | |
| Mondal et al. | Hematocrit (HCT) | |
| CN109470533B (en) | Preparation method of human whole blood matrix quality control product for portable glucometer | |
| Brainina et al. | New electrochemical method of determining blood and blood fractions antioxidant activity | |
| US10724953B2 (en) | Method for evaluating phagocytic capacity and fluorescence measurement method | |
| CN105368916A (en) | Prothrombin time assay kit and preparation method thereof | |
| JP2019060887A (en) | Blood condition analysis device, blood condition analysis system, blood condition analysis method, and blood condition analysis program for causing computer to execute the method | |
| Stephen et al. | Analytical comparison between microhematocrit and automated methods for packed cell volume (PCV) determination | |
| CA2514743C (en) | Performance improvement for hematology analysis | |
| WO1997015829A1 (en) | Measurement of carbon dioxide in blood | |
| CN109521201A (en) | A kind of source of people whole blood matrix quality-control product for portable glucose meter | |
| Beyan et al. | Is mean platelet volume and inflammatory activity really correlated in patients with ankylosing spondylitis? | |
| Chothia et al. | A method comparison study of a point-of-care blood gas analyser with a laboratory auto-analyser for the determination of potassium concentrations during hyperkalaemia in patients with kidney disease | |
| CN109998561B (en) | Disposable blood coagulation vacuum blood collection tube | |
| Salmond et al. | Comparison of point-of-care device DiaSpect against the HemoCue and laboratory analyser in an ICU population | |
| Jay | Method comparison: where do we draw the line? | |
| Dorofeykov et al. | Modern clinical blood tests in doping control initiatives | |
| Zilg et al. | A rapid method for postmortem vitreous chemistry-deadside analysis. Biomolecules. 2022; 12: 32 | |
| Pannu et al. | Warfarin related nephropathy: a case report from a tertiary hospital of north India and review of literature |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |